Cat. No.: HY-W013441

2',3'-Dideoxyadenosine

Name: 2',3'-Dideoxyadenosine
Brand: MedChemExpress
SKU: HY-W013441
Price: 51.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

고객리뷰

Based on 1 publication(s) in Google Scholar

2',3'-Dideoxyadenosine is an inhibitor of HIV replication. Antiretroviral activity. Antiviral efficacy.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.96%
CAS No.: 4097-22-7
화학식: C₁₀H₁₃N₅O₂
분자량:235.24

보관:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

2',3'-Dideoxyadenosine Chemical Structure

CAS No.: 4097-22-7

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

2',3'-Dideoxyadenosine is an inhibitor of HIV replication^[1]. Antiretroviral activity^[1]. Antiviral efficacy^[1].

IC₅₀ & Target

HIV-1

HIV-2

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
ATH-8 cell line	ED₅₀	2.7 μM Compound: ddAdo	Protection of ATH8 cells against the cytopathic effect of HIV. Protection of ATH8 cells against the cytopathic effect of HIV.	[PMID: 3497272]
ATH-8 cell line	ED₅₀	5 μM Compound: ddA	In vitro effective dose which provides 50% protection of ATH-8 cells against the cytopathic effect of HIV; range 5-10 uM In vitro effective dose which provides 50% protection of ATH-8 cells against the cytopathic effect of HIV; range 5-10 uM	[PMID: 1619614]
C3H/3T3	EC₅₀	39.1 μM Compound: dda (1)	Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts	[PMID: 10229630]
C3H/3T3	EC₅₀	40 μM Compound: 2	Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts	[PMID: 10229629]
C8166	ED₅₀	2 μM Compound: ddAdo	In vitro evaluation of anti-HIV-1 activity in C8166 cells infected with HIV-1 IIIB. In vitro evaluation of anti-HIV-1 activity in C8166 cells infected with HIV-1 IIIB.	[PMID: 7562937]
CCRF-CEM	CC₅₀	>100 μM Compound: ddA	Compound was evaluated for its concentration (potency) to inhibit the growth of CEM cells. Compound was evaluated for its concentration (potency) to inhibit the growth of CEM cells.	[PMID: 10498207]
CCRF-CEM	CC₅₀	>250 μM Compound: 2	In vitro cytotoxic concentration in CEM cells. In vitro cytotoxic concentration in CEM cells.	[PMID: 10229629]
CCRF-CEM	CC₅₀	>250 μM Compound: 3, ddA	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24177359]
CCRF-CEM	CC₅₀	>250 μM Compound: dda (1)	Cytotoxic concentration in Wild Type CEM cells Cytotoxic concentration in Wild Type CEM cells	[PMID: 10229630]
CCRF-CEM	CC₅₀	200 μM Compound: 1	Cytotoxic activity was evaluated against CEM/O cells Cytotoxic activity was evaluated against CEM/O cells	10.1016/S0960-894X(97)00265-5
CCRF-CEM	EC₅₀	2.8 μM Compound: 3, ddA	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	3.67 μM Compound: 1	Effective concentration of compound against HIV-1 infected CEM/O cells Effective concentration of compound against HIV-1 infected CEM/O cells	10.1016/S0960-894X(97)00265-5
CCRF-CEM	EC₅₀	4 μM Compound: ddA	Compound was evaluated for its effective concentration (potency) to inhibit the growth of HIV-1 in CEM cell culture. Compound was evaluated for its effective concentration (potency) to inhibit the growth of HIV-1 in CEM cell culture.	[PMID: 10498207]
CCRF-CEM	EC₅₀	4.33 μM Compound: dda (1)	Antiviral activity evaluated as the ability to inhibit the replication of HIV-1 in human T-lymphocytic cells (CEM) Antiviral activity evaluated as the ability to inhibit the replication of HIV-1 in human T-lymphocytic cells (CEM)	[PMID: 10229630]
CCRF-CEM	EC₅₀	4.55 μM Compound: dda (1)	Antiviral activity evaluated as the ability to inhibit the replication of HIV-2 in human T-lymphocytic cells (CEM) Antiviral activity evaluated as the ability to inhibit the replication of HIV-2 in human T-lymphocytic cells (CEM)	[PMID: 10229630]
CCRF-CEM	EC₅₀	5.33 μM Compound: 1	Effective concentration of compound against HIV-2 infected CEM/O cells Effective concentration of compound against HIV-2 infected CEM/O cells	10.1016/S0960-894X(97)00265-5
CCRF-CEM	EC₅₀	7.2 μM Compound: 3, ddA	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	8 μM Compound: ddA	Compound was evaluated for its effective concentration (potency) to inhibit the growth of HIV-2 in CEM cell culture. Compound was evaluated for its effective concentration (potency) to inhibit the growth of HIV-2 in CEM cell culture.	[PMID: 10498207]
CCRF-CEM	IC₅₀	>250 μM Compound: 3, ddA	Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CEM-SS	CC₅₀	>100 μM Compound: ddA	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability	[PMID: 34695774]
CEM-SS	CC₅₀	>110 μM Compound: ddA	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
HeLa	IC₅₀	>250 μM Compound: 3, ddA	Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HepG2	EC₅₀	6 μM Compound: 8 beta-Ld2A	Antiviral activity against Hepatitis B virus in 2.2.15 cell line Antiviral activity against Hepatitis B virus in 2.2.15 cell line	10.1016/0960-894X(96)00293-4
HepG2	IC₅₀	>200 μM Compound: 8 beta-Ld2A	Concentration required to inhibit 50% of 2.2.15 cell line Concentration required to inhibit 50% of 2.2.15 cell line	10.1016/0960-894X(96)00293-4
L1210	IC₅₀	>250 μM Compound: 3, ddA	Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
MT4	CC₅₀	>100 μM Compound: D4A	Concentration required to reduce the number of viable uninfected MT-4 cells by 50%. Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.	[PMID: 1495007]
MT4	CC₅₀	>100 μM Compound: ddA	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19282192]
MT4	CC₅₀	>100 μM Compound: ddA	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 34695774]
MT4	CC₅₀	>110 μM Compound: ddA	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
MT4	CC₅₀	>500 μM Compound: DDA	Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect	[PMID: 2016715]
MT4	CC₅₀	890 μM Compound: DDA	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	CC₅₀	890 μM Compound: ddAdo	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	EC₅₀	41 μM Compound: D4A	Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity. Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.	[PMID: 1495007]
MT4	EC₅₀	5.2 μM Compound: ddA	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	6.3 μM Compound: DDA	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).	[PMID: 1992136]
MT4	EC₅₀	6.3 μM Compound: DDA	Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	6.3 μM Compound: ddAdo	Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1	[PMID: 2479745]
MT4	EC₅₀	7.2 μM Compound: DDA	Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells	[PMID: 2016715]
MT4	EC₅₀	72 μM Compound: D4A	Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity. Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.	[PMID: 1495007]
MT4	ED₅₀	6.2 μM Compound: 1	Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction	[PMID: 3499515]
MT4	ED₅₀	6.4 μM Compound: ddAdo	Inhibitory activity against HIV-1 replication in MT-4 cells Inhibitory activity against HIV-1 replication in MT-4 cells	[PMID: 2754700]
PBMC	CC₅₀	>100 μM Compound: ddA	Cytotoxicity against human PBMC assessed as reduction in cell viability Cytotoxicity against human PBMC assessed as reduction in cell viability	[PMID: 34695774]
PBMC	EC₅₀	0.24 μM Compound: ddA	Anti-HIV activity against HIV-1 infected in human PBMC assessed as inhibition of viral replication Anti-HIV activity against HIV-1 infected in human PBMC assessed as inhibition of viral replication	[PMID: 34695774]

In Vitro

2',3'-Dideoxyadenosine inhibits HIV-1 and? simian immunodeficiency virus (SIV) in MT-4 cells with EC₅₀s of 5.27 and 5.3 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in human T-lymphocyte CEM cells with EC₅₀s of 4 μM and 8 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in Molt 4/C8 cells with EC₅₀s of 4 μM and 5.5 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in C8166 cells with EC₅₀s of 17 μM and 22 μM, respectively. 2',3'-Dideoxyadenosine inhibits murine sarcoma virus (MSV) in C3H/3T3 cells with an EC₅₀ of 24 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 4097-22-7
Appearance Solid
분자량 235.24
화학식 C₁₀H₁₃N₅O₂
Color White to off-white
SMILES

OC[C@@H]1CC[C@H](N2C(N=CN=C3N)=C3N=C2)O1
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Brain Behav Immun

Dexamethasone attenuates neuropathic pain through spinal microglial expression of dynorphin A via the cAMP/PKA/p38 MAPK/CREB signaling pathway. [Abstract]

2024 Jul:119:36-50. PMID: 38555991

용액&용해도

In Vitro:

DMSO : 125 mg/mL (531.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2510 mL

21.2549 mL

42.5098 mL

5 mM

0.8502 mL

4.2510 mL

8.5020 mL

10 mM

0.4251 mL

2.1255 mL

4.2510 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Balzarini J, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997 Jun 30;410(2-3):324-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2510 mL	21.2549 mL	42.5098 mL	106.2744 mL
	5 mM	0.8502 mL	4.2510 mL	8.5020 mL	21.2549 mL
	10 mM	0.4251 mL	2.1255 mL	4.2510 mL	10.6274 mL
	15 mM	0.2834 mL	1.4170 mL	2.8340 mL	7.0850 mL
	20 mM	0.2125 mL	1.0627 mL	2.1255 mL	5.3137 mL
	25 mM	0.1700 mL	0.8502 mL	1.7004 mL	4.2510 mL
	30 mM	0.1417 mL	0.7085 mL	1.4170 mL	3.5425 mL
	40 mM	0.1063 mL	0.5314 mL	1.0627 mL	2.6569 mL
	50 mM	0.0850 mL	0.4251 mL	0.8502 mL	2.1255 mL
	60 mM	0.0708 mL	0.3542 mL	0.7085 mL	1.7712 mL
	80 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3284 mL
	100 mM	0.0425 mL	0.2125 mL	0.4251 mL	1.0627 mL

Bioz

Keywords

2',3'-Dideoxyadenosine

1 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

2',3'-Dideoxyadenosine

Adenosine

Stavudine

2',3'-cGAMP

Zalcitabine

Zidovudine

2',3'-Dideoxyuridine